Cost-Effectiveness of Cyclooxygenase-2 Inhibitors in Chronic Arthritis
Authors: Brennan M.R. Spiegel, Ian M. Gralnek
Journal: Annals of Internal Medicine (2004)

Letters4 May 2004Cost-Effectiveness of Cyclooxygenase-2 Inhibitors in Chronic ArthritisBrennan M.R. Spiegel, MD and Ian M. Gralnek, MD, MSHSBrennan M.R. Spiegel, MDFrom Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA 90073.Search for more papers by this author and Ian M. Gralnek, MD, MSHSFrom Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA 90073.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-9-200405040-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Pellissier and colleagues for their interest in our study. Whereas we estimated that it costs more than $275 000 per quality-adjusted life-year gained to prescribe a coxib in lieu of naproxen in average-risk patients with arthritis, Pellissier and colleagues came to very different conclusions. Specifically, the authors estimated that it costs only $4738 more per ulcer complication avoided to use a coxib instead of a nonselective NSAID when clinical data are incorporated, and further concluded that coxibs dominate when endoscopic data are considered (1). Our statement that Pellissier and colleagues found that rofecoxib was “more effective ...References1. Pellissier JM, Straus WL, Watson DJ, Kong SX, Harper SE. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. Clin Ther. 2001;23:1061-79. [PMID: 11519771] CrossrefMedlineGoogle Scholar2. 2003 Red Book of Average Wholesale Drug Prices. Montvale, NJ: Thompson Medical Economics; 2003. Google Scholar3. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al . Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104-10. [PMID: 12501222] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Brennan M.R. Spiegel, MD; Ian M. Gralnek, MD, MSHSAffiliations: From Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA 90073. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMisoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs Fred E. Silverstein , David Y. Graham , John R. Senior , Helen Wyn Davies , Barbara J. Struthers , Richard M. Bittman , and G. Steven Geis The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis Brennan M.R. Spiegel , Laura Targownik , Gareth S. Dulai , and Ian M. Gralnek Cost-Effectiveness of Cyclooxygenase-2 Inhibitors in Chronic Arthritis James M. Pellissier , Douglas J. Watson , Sheldon X. Kong , and Walter L. Straus Metrics Cited byReaching and influencing consumers in the prescription medicine market 4 May 2004Volume 140, Issue 9Page: 761-762KeywordsAdverse reactionsArthritisDecision treesGastroenterology and hepatologyIbuprofenNSAIDsProphylaxisProton pump inhibitorsQuality adjusted life yearsUlcers ePublished: 4 May 2004 Issue Published: 4 May 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...